作为医疗类主题的权益基金，泰康医疗健康股票自然重仓医药股，从今年三季报中的前十大重仓股 看，该基金持有晶泰控股、康龙化成、方舟健客、三生制药、昭衍新药、九安医疗、奕瑞科技、羚锐制 药、百普赛斯、毕得医药。但从走势上看，尽管多数个股在三季度都随市场整体上涨而大涨，然而其 A/C份额在三季度里却仅上涨了5.43%和5.30%，不知道是不是多数重仓股已经被更换的原因。 如果仅以三季度的重仓股看，进入到四季度，这些个股大都出现回调，比如第一大重仓股晶泰控股 就在四季度以来下跌了近35%，方舟健客更是在10月份后大跌38%，还有多只个股跌幅都超过10%。而 唯一一只今年前三个季度始终出现在前十大重仓股中的羚锐制药，股价在2025年度内还处于小幅下跌状 态。 (责任编辑：康博) 来源：天天基金网 中国经济网北京12月17日讯 今日，新浪发布《牛市亏损！泰康基金："医疗健康A"年内净值下跌 12.54%，成立以来仍处于浮亏》一文。文中称，截至2025年12月15日，泰康医疗健康A年内净值下跌 12.54%，成立3年多该基金净值累计跌超8%。该基金部分三季度末重仓股自四季度以来股价下跌超过 30%，包括晶泰控股、方舟健客等。 ...

Core Insights - The article discusses the recent developments in the pharmaceutical industry, particularly focusing on the approval of innovative drugs and their market implications [12][15]. Market Performance - The pharmaceutical and biotechnology indices experienced a slight decline, with the medical biotechnology index down by 0.29%, outperforming the Shanghai Composite Index by 0.05 percentage points [5]. - The Hang Seng Healthcare Index fell by 2.26%, while the Hong Kong innovative drug ETF decreased by 2.18% [5]. Innovative Drug Approvals - Eight innovative drugs received approval last week, including: - **Fitusiran** for hemophilia A or B [11]. - **库莫西利** (Kumosili), a CDK2/4/6 inhibitor for HR+/HER2- breast cancer, which is expected to address resistance issues seen with existing treatments [12][14]. - **玛帕西沙韦** (Marpasiwe), an antiviral for influenza, showing significant efficacy in clinical trials [15]. Clinical Trials and Research - The article highlights ongoing clinical trials, including a significant Phase III trial for **库莫西利**, which demonstrated a median progression-free survival (PFS) of 16.62 months, extending PFS by 9.16 months compared to the control group [14]. - A total of 96 new clinical trial registrations were disclosed, with 30 trials in Phase II or higher [7]. Industry Trends - The innovative drug sector remains a key investment focus, with ongoing business development activities and cross-border transactions indicating strong confidence in domestic innovation capabilities [6]. - The global market for CDK4/6 inhibitors is projected to reach approximately $24 billion, driven by increasing indications for early-stage breast cancer [12]. Challenges - The article notes that resistance to CDK4/6 inhibitors remains a significant challenge, with about 20% of HR+ breast cancer patients showing primary resistance to endocrine therapy [12].

Group 1 - The Hang Seng Index rose by 0.22%, gaining 55 points to reach 25,291 points, while the Hang Seng Tech Index increased by 0.02% with a trading volume of 84.8 billion HKD in the morning session [1] - Yichun City announced the cancellation of 27 mining rights, leading to a surge in lithium stocks, with Ganfeng Lithium rising over 6% and Tianqi Lithium increasing by over 5% [1] - Airlines showed strong performance in passenger load factors during the off-peak season, with Southern Airlines up over 7%, Eastern Airlines up over 5%, and Air China rising by 5% [1] Group 2 - Jiaxin International Resources saw a 6% increase as tungsten market prices accelerated, with tungsten concentrate prices hitting a historical high [1] - Junda Co., Ltd. rose over 6% as its Chuzhou base achieved large-scale production of TOPCon batteries [1] - Longi Green Energy's fiber optic cable business surged nearly 11% due to increased demand for AI computing power [1] Group 3 - Yaojie Ankang-B experienced an 18% increase after announcing positive clinical results for Tiengatin in a publication by The Lancet [1] - Li Ning Company rose by 4% with the launch of new flagship stores and a collaboration with the Honor Gold Standard product series, expected to create strong synergies [1] - China Education Holdings increased by 6% as its adjusted EBITDA exceeded expectations, with institutions focusing on the progress of subsequent classification registration [1] Group 4 - Ganwan saw a rise of over 4%, accumulating over 30% growth this month, in partnership with COEXIST to expand its trendy toy industry layout [2] - Zhaoyan New Drug increased by over 10% due to rising prices of experimental monkeys, with institutions predicting a tight supply-demand situation [3] - Yidu International fell over 12% in the morning session, giving back most of its gains for the month, while Muxi Co., Ltd. was listed on the Sci-Tech Innovation Board today [3]

Group 1 - Century United Holdings (01959) resumed trading with an initial increase of over 33%, currently up 4.24%. The company announced a cash deal of approximately HKD 153 million for the acquisition of about 377 million shares, representing 71.12% of the total issued share capital, at HKD 0.405 per share [1] - Changfei Optical Fiber (06869) rose over 10% following a report from Huatai Securities indicating that the company's optical fiber and cable business is benefiting from AI computing demand, leading to continuous product structure optimization [1] - Kangnait Optical (02276) increased by over 5% after the launch of Quark AI glasses, marking Alibaba's entry into the AI glasses market [1] - Tanwan, a subsidiary of Tanwan (09890), signed a cooperation agreement with COEXIST Group for artist work development, contributing to a monthly increase of over 30% in stock price, currently up 4.34% [1] Group 2 - Yaojie Ankang-B (02617) surged nearly 14%, currently up 18.57%. The company announced that its core product, Tiengotine, has published exploratory Phase II clinical results for cholangiocarcinoma in a high-impact journal [2] - China Silver Group (00815) rose over 7% as spot silver prices exceeded USD 65 per ounce, marking one of the strongest rebounds in commodities for 2025 [2] - Yidu International (00259) fell over 12%, currently down 12.67%, as Muxi shares debuted on the STAR Market with a 568% opening increase, reaching a market cap of CNY 280 billion [2] - Gaoya Optical (00907) experienced a significant drop of 40%, currently down 34.67%, after receiving a notice from the stock exchange regarding insufficient operational levels to maintain listing [2] Group 3 - Zhaoyan New Drug (06127) increased by over 10% as the market focused on the rising prices of preclinical evaluation test assets, with experimental monkeys priced at approximately CNY 140,000 each [3] Group 4 - Airline stocks saw gains, with Eastern Airlines (00670) up 5.66%, Air China (00753) up 5.56%, and Southern Airlines (01055) up 7.22%. Recent operational data showed strong passenger load factors for November, with Eastern Airlines at 87.37%, Southern Airlines at 86.29%, and Air China at 83.3% [4] Group 5 - Pfizer (PFE.US) fell 3.41% as the company predicts minimal sales growth next year due to costly acquisitions aimed at refreshing its drug portfolio [5] - Quantum computing stocks saw collective gains, with IonQ Inc (IONQ.US) up 7.81%, D-Wave Quantum (QBTS.US) up 7.5%, and others showing similar increases [5] - Hesai Technology (HSAI.US) rose 3.64% as the company announced its participation in CES 2026 in Las Vegas [5] - Pony.ai (PONY.US) increased by 7.28% following the announcement of the first batch of L3 autonomous driving vehicle approvals in China [5] Group 6 - Lemonade (LMND.US) rose 8.38% after Morgan Stanley upgraded the stock to hold and raised the target price from USD 53 to USD 85 [6] - Seagate Technology (STX.US) increased by 0.89% as Morgan Stanley reiterated its "overweight" rating, expecting continued demand for hard disk drives until 2027 [6] - Bitcoin-related stocks rebounded strongly, with Strategy (MSTR.US) up 3.34%, Circle (CRCL.US) up 9.99%, and Coinbase (COIN.US) up 0.87%, as Bitcoin prices returned above USD 87,000 [6] - UBS (UBS.US) rose 4.94%, reaching its highest price since 2008, following a proposed compromise on new capital rules by Swiss lawmakers [6]

Group 1 - The Hang Seng Index rose by 0.22%, gaining 55 points to reach 25,291 points, while the Hang Seng Tech Index increased by 0.02% with a trading volume of 84.8 billion HKD in the morning session [1] - Yichun City announced the cancellation of 27 mining rights, leading to a surge in lithium stocks, with Ganfeng Lithium rising over 6% and Tianqi Lithium increasing by over 5% [1] - Airlines showed strong performance in November's off-peak season, with Southern Airlines up over 7%, Eastern Airlines up over 5%, and Air China rising by 5% [1] Group 2 - Jiangxi International Resources saw a 6% increase as tungsten prices accelerated, reaching a historical high for tungsten concentrate [1] - Junda Co., Ltd. rose over 6% after its Chuzhou base achieved large-scale production of TOPCon batteries [1] - Changfei Optical Fiber and Cable increased by nearly 11% driven by AI computing power demand [2] Group 3 - Yaojie Ankang-B surged by 18% after announcing positive clinical results for Tiengatin in a sub-journal of The Lancet [3] - Li Ning rose by 4% with the launch of new Dragon Store and Honor Gold Standard product series, expected to create strong synergy [4] - Zhongjiao Holdings increased by 6% as its adjusted annual EBITDA exceeded expectations, with institutions focusing on subsequent classification registration progress [5] Group 4 - Tanwan rose over 4%, accumulating over 30% growth this month, partnering with COEXIST to expand its trendy toy industry layout [6] - Zhaoyan Pharmaceutical increased by over 10% as the price of experimental monkeys rose, with institutions expecting a tight supply-demand situation to persist [7] - Yidu International fell over 12% in the morning session, giving back most of its gains for the month, as Muxi Co., Ltd. listed on the Sci-Tech Innovation Board today [8]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Zhaoyan New Drug (6127.HK), which increased nearly 10% to HKD 22.48, marking a two-month high, with a cumulative increase of over 30% in December, leading to a total market capitalization of HKD 16.86 billion [1] - The price of experimental monkeys has surged, with the cost of 3-5 year old crab-eating macaques reaching HKD 140,000 each, indicating a supply-demand imbalance this year [1] - The recovery in the CRO (Contract Research Organization) industry and the upward cycle of innovative drugs are contributing factors to the rising prices of experimental monkeys, with several CRO companies, including Zhaoyan New Drug and Yinos, having substantial resources in this area [1] Group 2 - According to Founder Securities, leading CROs with rich strategic resource reserves are expected to benefit from the industry recovery and the fair value gains from monkey prices [1] - For Zhaoyan New Drug, assuming an average price of HKD 84,900 per monkey in 2024 and an increase to HKD 140,000 by Q4 2025, with an estimated output rate of 17% from 23,200 monkeys, the projected new fair value in 2025 could be approximately HKD 220 million [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Zhaoyan New Drug (6127.HK), which increased nearly 10% to HKD 22.48, marking a two-month high, with a cumulative increase of over 30% in the month, resulting in a total market capitalization of HKD 16.86 billion [1] - The price of experimental monkeys has surged, with the cost for 3-5 year old crab-eating macaques reaching HKD 140,000 each, indicating a supply-demand imbalance this year [1] - The increase in monkey prices is linked to the upward cycle of innovative drugs and the recovery of orders in the CRO industry, with several CRO companies, including Zhaoyan New Drug and Yinos, having substantial resources in experimental monkeys [1] Group 2 - According to Founder Securities, leading CROs with rich strategic resource reserves are expected to benefit from the industry recovery and the fair value gains from monkey prices [1] - For Zhaoyan New Drug, assuming an average price of HKD 84,900 per monkey in 2024 and an increase to HKD 140,000 by Q4 2025, with an estimated output rate of 17% from a known 23,200 monkeys, the projected new fair value in 2025 could be approximately HKD 220 million [1]

Core Viewpoint - The stock of Zhaoyan New Drug (06127) has risen over 8%, currently trading at 22.14 HKD, with a transaction volume of 39.86 million HKD, driven by increasing demand for preclinical safety evaluation assets, specifically macaques [1] Group 1: Market Dynamics - The price of experimental macaques has shown a rapid upward trend, reaching approximately 140,000 RMB per macaque as of December 9, 2025 [1] - The demand for macaques, a critical resource for preclinical safety evaluations, is expected to increase as orders for preclinical CROs recover steadily [1] - Supply-side expansion is challenging in the short term, with some macaque farms indicating that their production capacity is already booked until Q1 2026, suggesting a tight supply-demand balance that may lead to further price increases [1] Group 2: Company Insights - Leading CROs with abundant strategic resource reserves are likely to benefit from the industry's recovery and the fair value gains from macaque prices [1] - For Zhaoyan New Drug, assuming an average price of 84,900 RMB per macaque in 2024 and an increase to 140,000 RMB by Q4 2025, the estimated new fair value addition in 2025 could be around 220 million RMB, based on a known population of 23,200 macaques and a 17% output rate [1]

每经AI快讯，昭衍新药(06127.HK)涨超8%，截至发稿涨8.21%，报22.14港元，成交额3986.2万港元。 （文章来源：每日经济新闻） ...

Macro Overview - In November, the US added 64,000 non-farm jobs, exceeding Bloomberg's consensus estimate of 50,000, while October saw a decline of 105,000 [2] - The unemployment rate rose by 0.2 percentage points to 4.6% compared to September, with the labor participation rate increasing by 0.1 percentage points to 62.5% [2] - Hourly wage growth slowed to 0.1% month-on-month, down from an expected 0.3% [2] - The market has slightly increased the expectation of cumulative interest rate cuts in 2026 to 60 basis points [2] Automotive Industry - The Ministry of Industry and Information Technology granted conditional approval for the first L3 vehicles from Changan and BAIC Blue Valley, marking a significant step towards the practical application of L3 autonomous driving technology [3] - The approval is expected to accelerate the restructuring of the smart driving industry chain, with significant investment opportunities in smart vehicles, control chassis, domain control chips, and lidar [3] Construction and Building Materials - From January to November 2025, infrastructure investment (excluding power, heat, gas, and water supply) decreased by 1.1%, real estate by 15.9%, and manufacturing by 1.9% year-on-year, indicating pressure on investment demand [4] - The central political bureau emphasized the need to stabilize investment and expand domestic demand, suggesting that infrastructure investment may see a rebound [4] - Recommended stocks include Yaxiang Integrated, Meiyu Technology, Sichuan Road and Bridge, China National Materials, China Jushi, Huaxin Cement, Dongfang Yuhong, and Tubao [4] Real Estate Market - The report discusses the urgency of revitalizing the US real estate market under the Trump administration, focusing on improving housing affordability and mortgage liquidity as primary goals [5] - The report anticipates that short-term policies may focus on lowering mortgage rates and easing credit access, which could have expansionary effects on the economy but may exacerbate long-term structural issues [5] CXO Industry - The CXO industry is experiencing marginal improvements due to external factors, with expectations of a new high-growth cycle driven by overseas interest rate cuts and domestic recovery [10] - The report highlights the core competitiveness of Chinese CXO firms in efficiency, cost, quality, and rapid expansion capabilities, with a recommendation for leading firms such as WuXi AppTec and Kelaiying [10] Internet Sector - The local life market in Q3 2025 showed signs of optimization in the ride-hailing sector and expansion in the food delivery sector, with significant regional growth disparities [11] - The report indicates that the overall profit margin in the industry is on an upward trajectory, with expectations for annual profit margin expansion in the ride-hailing and food delivery segments [11] - Recommended companies include Meituan, Dash, Grab, and Uber [11]